Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 oncolytic adenovirus plus PD-1 inhibitor in metastatic castration-resistant prostate cancer
ChiCTR2500105156Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine and serplulimab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Radiological progression-free survival and Objective response rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
Oncorineserplulimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2500105156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105156.